Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Coccidiodes immitis, 7, 19

dengue virus, 345–346

diabetes, 387

Epstein-Barr virus, 329, 333

funding, 125

gonorrhea, 371

herpes simplex virus, 327

mycobacterium tuberculosis, 352, 353–354, 355

papillomaviruses, 342

programmed T-cell death, 397–398

respiratory syncytial virus, 6, 19

streptococcus, group A, 362, 363

Cloning, 26, 36

Coccidiodes immitis, 7, 19, 44, 54, 88, 90, 91, 159–164, 356–359

Cognitive impairments, 62, 64–65

Combination vaccines, 9, 18, 38, 46–47, 75, 130, 436

elicobacter pylori, 364, 366–367

herpes simplex virus, 327

Computer technology

committee’s model, application of, 13, 95

Internet, IOM, 4, 323

physician reminders, 48

Confidentiality, 47

Conjugate vaccines

Haemophilus influenzae, 11

varicella-zoster virus, 11, 18

Cost and cost-effectiveness analysis, general, 2–3, 11, 12, 17, 20, 435–436, 437

age factors, analytic approach of model, 60, 66, 68–69, 80–83, 84

age factors, detailed review of model, 93, 95, 98–100, 101–103, 105

aggregation, 2, 56, 117–118, 119

children, 46

combination vaccines, 47

death rates, analytic approach of model, 61–62, 66, 68, 78–79, 80–83, 86

death rates, detailed characterization of model, 95, 97–98, 100, 103–104

defined, 56

discounting, 18, 60–61, 68–69, 74, 80, 83, 85–86, 97–98, 99, 101–103, 105–107, 114–115

ethical issues, 3–4, 58, 75, 109–122, 128, 129

licensure possibilities, scope of study at hand, 39, 40, 43

licensure process, 19–20, 54–55, 58;

see also Time factors

life expectancy, analytic approach of model, 57, 66, 68, 76, 120

life expectancy, detailed characterization of model, 95–96, 98, 99, 101–102, 103, 104, 106–107

mathematical formulae, 94–97, 99, 101–106 (passim)

model, analytical approach, 53–92

model, detailed description, 93–108

morbidity/morbidity scenarios, analytic approach of model, 61–66, 67, 68, 69, 71, 76, 78–79, 80–85

morbidity/morbidity scenarios, detailed characterization of model, 95, 96, 97, 98, 108

opportunity costs, 74, 115–116, 130

polio, 25–26

pregnant women, 22

ranking of vaccines covered, 5–8

reasons for, 57

sensitivity analysis, 3, 57

specific diseases/pathogens/vaccines,

lists of, 54–55, 87–91

review for each, 143–433;

see also diseases/pathogens/vaccines found in lists

utilization of vaccines, analytic approach of model, 72–73, 75, 76, 79, 80, 86, 88, 89, 91

utilization of vaccines, detailed characterization of model, 95, 107–108

see also Death rates; Efficacy of vaccines; Morbidity scenarios; Quality-adjusted life years

Contraceptive vaccines, 75–76

Costimulation, 372, 373, 375, 389, 398, 399, 400, 401, 402, 407–412, 419



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement